首页 > 最新文献

Technology in Cancer Research & Treatment最新文献

英文 中文
Machine Learning-Based Pathomics Model to Predict the Prognosis in Clear Cell Renal Cell Carcinoma. 基于机器学习的病理模型预测透明细胞肾细胞癌的预后。
IF 2.7 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 DOI: 10.1177/15330338241307686
Xiangyun Li, Xiaoqun Yang, Xianwei Yang, Xin Xie, Wenbin Rui, Hongchao He

Clear cell renal cell carcinoma (ccRCC) is a highly lethal urinary malignancy with poor overall survival (OS) rates. Integrating computer vision and machine learning in pathomics analysis offers potential for enhancing classification, prognosis, and treatment strategies for ccRCC. This study aims to create a pathomics model to predict OS in ccRCC patients. In this study, data from ccRCC patients in the TCGA database were used as a training set, with clinical data serving as a validation set. Pathological features were extracted from H&E-stained slides using PyRadiomics, and a pathomics model was constructed using the non-negative matrix factorization (NMF) algorithm. The model's predictive performance was assessed through Kaplan-Meier (KM) survival curves and Cox regression analysis. Additionally, differential gene expression, gene ontology (GO) enrichment analysis, immune infiltration, and mutational analysis were conducted to investigate the underlying biological mechanisms. A total of 368 pathomics features were extracted from H&E-stained slides of ccRCC patients, and a pathomics model comprising two subtypes (Cluster 1 and Cluster 2) was successfully constructed using the NMF algorithm. KM survival curves and Cox regression analysis revealed that Cluster 2 was associated with worse OS. A total of 76 differential genes were identified between the two subtypes, primarily involving extracellular matrix organization and structure. Immune-related genes, including CTLA4, CD80, and TIGIT, were highly expressed in Cluster 2, while the VHL and PBRM1 genes, along with mutations in the PI3K-Akt, HIF-1, and MAPK signaling pathways, exhibited mutation rates exceeding 40% in both subtypes. The machine learning-based pathomics model effectively predicts the OS of ccRCC patients and differentiates between subtypes. The critical roles of the immune-related gene CTLA4 and the PI3K-Akt, HIF-1, and MAPK signaling pathways offer new insights for further research on the molecular mechanisms, diagnosis, and treatment strategies for ccRCC.

透明细胞肾细胞癌(ccRCC)是一种高致死率的泌尿系统恶性肿瘤,总生存率较低。在病理分析中整合计算机视觉和机器学习为ccRCC的分类、预后和治疗策略提供了潜力。本研究旨在建立一个预测ccRCC患者OS的病理模型。本研究使用TCGA数据库中ccRCC患者的数据作为训练集,临床数据作为验证集。利用PyRadiomics从h&e染色的切片中提取病理特征,并利用非负矩阵分解(NMF)算法构建病理模型。通过Kaplan-Meier (KM)生存曲线和Cox回归分析评估模型的预测性能。此外,通过差异基因表达、基因本体(GO)富集分析、免疫浸润和突变分析来探讨潜在的生物学机制。从h&e染色的ccRCC患者载玻片中提取了368个病理特征,利用NMF算法成功构建了包含2个亚型(Cluster 1和Cluster 2)的病理模型。KM生存曲线和Cox回归分析显示,第2组与较差的OS相关。在两个亚型之间共鉴定出76个差异基因,主要涉及细胞外基质组织和结构。免疫相关基因,包括CTLA4、CD80和TIGIT,在集群2中高表达,而VHL和PBRM1基因,以及PI3K-Akt、HIF-1和MAPK信号通路的突变,在这两个亚型中均表现出超过40%的突变率。基于机器学习的病理模型有效地预测了ccRCC患者的OS并区分了亚型。免疫相关基因CTLA4和PI3K-Akt、HIF-1和MAPK信号通路的关键作用为进一步研究ccRCC的分子机制、诊断和治疗策略提供了新的见解。
{"title":"Machine Learning-Based Pathomics Model to Predict the Prognosis in Clear Cell Renal Cell Carcinoma.","authors":"Xiangyun Li, Xiaoqun Yang, Xianwei Yang, Xin Xie, Wenbin Rui, Hongchao He","doi":"10.1177/15330338241307686","DOIUrl":"10.1177/15330338241307686","url":null,"abstract":"<p><p>Clear cell renal cell carcinoma (ccRCC) is a highly lethal urinary malignancy with poor overall survival (OS) rates. Integrating computer vision and machine learning in pathomics analysis offers potential for enhancing classification, prognosis, and treatment strategies for ccRCC. This study aims to create a pathomics model to predict OS in ccRCC patients. In this study, data from ccRCC patients in the TCGA database were used as a training set, with clinical data serving as a validation set. Pathological features were extracted from H&E-stained slides using PyRadiomics, and a pathomics model was constructed using the non-negative matrix factorization (NMF) algorithm. The model's predictive performance was assessed through Kaplan-Meier (KM) survival curves and Cox regression analysis. Additionally, differential gene expression, gene ontology (GO) enrichment analysis, immune infiltration, and mutational analysis were conducted to investigate the underlying biological mechanisms. A total of 368 pathomics features were extracted from H&E-stained slides of ccRCC patients, and a pathomics model comprising two subtypes (Cluster 1 and Cluster 2) was successfully constructed using the NMF algorithm. KM survival curves and Cox regression analysis revealed that Cluster 2 was associated with worse OS. A total of 76 differential genes were identified between the two subtypes, primarily involving extracellular matrix organization and structure. Immune-related genes, including CTLA4, CD80, and TIGIT, were highly expressed in Cluster 2, while the VHL and PBRM1 genes, along with mutations in the PI3K-Akt, HIF-1, and MAPK signaling pathways, exhibited mutation rates exceeding 40% in both subtypes. The machine learning-based pathomics model effectively predicts the OS of ccRCC patients and differentiates between subtypes. The critical roles of the immune-related gene CTLA4 and the PI3K-Akt, HIF-1, and MAPK signaling pathways offer new insights for further research on the molecular mechanisms, diagnosis, and treatment strategies for ccRCC.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"23 ","pages":"15330338241307686"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11662324/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142865398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Narrative Review: Cardiotoxicities and Cardiac-Sparing Techniques in Radiotherapy. 叙述性回顾:放疗中的心脏毒性和心脏保留技术。
IF 2.7 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 DOI: 10.1177/15330338241301211
Maria F Chan, Dhwani Parikh, Chengyu Shi

This review article aims to synthesize existing data on radiation-induced heart diseases in patients undergoing chest radiation therapy and also explores cardiac-sparing techniques to mitigate cardiotoxic effects. We conducted a comprehensive database search to review and consolidate data regarding chest radiotherapy and effects on the heart as well as techniques to minimize exposure to the heart. The research findings demonstrate associations between radiation exposure to cardiac substructures and subsequent cardiotoxicity. This review also stresses the importance of identifying patients at high-risk for cardiotoxicity as well as advocates for the adoption of stringent cardiac dose constraints in these patients. Advanced cardiac-sparing techniques, notably respiratory motion management, have emerged as pivotal strategies to minimize the likelihood of cardiac events. This narrative review emphasizes the critical role of these innovations in optimizing cardiac health during radiation treatment.

这篇综述文章的目的是综合现有的数据,辐射诱发心脏疾病的患者接受胸部放射治疗,并探讨心脏保留技术,以减轻心脏毒性的影响。我们进行了一个全面的数据库搜索,以回顾和巩固有关胸部放疗和对心脏的影响以及减少心脏暴露的技术的数据。研究结果表明,辐射暴露于心脏亚结构与随后的心脏毒性之间存在关联。本综述还强调了识别心脏毒性高危患者的重要性,并倡导对这些患者采用严格的心脏剂量限制。先进的心脏保护技术,特别是呼吸运动管理,已经成为减少心脏事件可能性的关键策略。这篇叙述性综述强调了这些创新在优化放射治疗期间心脏健康方面的关键作用。
{"title":"Narrative Review: Cardiotoxicities and Cardiac-Sparing Techniques in Radiotherapy.","authors":"Maria F Chan, Dhwani Parikh, Chengyu Shi","doi":"10.1177/15330338241301211","DOIUrl":"10.1177/15330338241301211","url":null,"abstract":"<p><p>This review article aims to synthesize existing data on radiation-induced heart diseases in patients undergoing chest radiation therapy and also explores cardiac-sparing techniques to mitigate cardiotoxic effects. We conducted a comprehensive database search to review and consolidate data regarding chest radiotherapy and effects on the heart as well as techniques to minimize exposure to the heart. The research findings demonstrate associations between radiation exposure to cardiac substructures and subsequent cardiotoxicity. This review also stresses the importance of identifying patients at high-risk for cardiotoxicity as well as advocates for the adoption of stringent cardiac dose constraints in these patients. Advanced cardiac-sparing techniques, notably respiratory motion management, have emerged as pivotal strategies to minimize the likelihood of cardiac events. This narrative review emphasizes the critical role of these innovations in optimizing cardiac health during radiation treatment.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"23 ","pages":"15330338241301211"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11622324/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142787099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune Checkpoint Inhibitor Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Review and Meta-Analysis. 免疫检查点抑制剂加化疗作为晚期胃癌或胃食管交界癌的一线治疗:系统回顾与元分析》。
IF 2.7 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 DOI: 10.1177/15330338241273286
Lianghui Zhang, Lingli Huang, Zhixian Liu, Tao Ling

Background: Immune checkpoint inhibitor (ICI) plus chemotherapy is effective in advanced gastric or gastroesophageal junction (G/GEJ) cancer. This study aims to evaluate the clinical effect of first-line immunotherapy in combination with chemotherapy for advanced G/GEJ cancer. Methods: PubMed, Web of Science, Embase and Cochrane databases were systematically searched from the inception of the databases to December 2021. Randomized trials comparing ICI plus chemotherapy with chemotherapy in first-line treatment for advanced G/GEJ cancer were included. The outcomes were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and adverse events (AEs). Analyses were performed in Stata 14.0 software. The study protocol was registered with PROSPERO, number CRD42022300907. Results: Five trials were included for analysis, involving 2, 814 patients. ICI plus chemotherapy can significantly improve OS (hazards ratio [HR], 0.86; 95% CI 0.78-0.94; P = .002), PFS (HR, 0.79; 95% CI 0.63-0.99; P < .001) and ORR (relative ratio [RR], 1.20; 95% CI 1.11-1.30; P < .001). In safety analyses, there were no significant differences in incidence of all AEs, treatment-related adverse event (TRAE), TRAE of grade 3 or higher, serious TRAE and TRAE leading to death between two arms (P > .05). Conclusions: ICI plus chemotherapy is more effective first-line treatment for advanced G/GEJ cancer in contrast to chemotherapy regrading to improving OS, PFS and ORR, without increasing TRAE risk. This study will redefine the role of ICI in combination with chemotherapy in the first-line setting for G/GEJ cancer, and provide reference for clinical treatment.

背景:免疫检查点抑制剂(ICI)联合化疗对晚期胃癌或胃食管交界处癌(G/GEJ)有效。本研究旨在评估一线免疫疗法联合化疗治疗晚期G/GEJ癌的临床效果。研究方法系统检索了 PubMed、Web of Science、Embase 和 Cochrane 数据库中从数据库建立之初到 2021 年 12 月的内容。纳入了在晚期G/GEJ癌一线治疗中比较ICI加化疗与化疗的随机试验。研究结果包括总生存期(OS)、无进展生存期(PFS)、客观反应率(ORR)和不良事件(AEs)。分析在 Stata 14.0 软件中进行。研究方案已在 PROSPERO 注册,编号为 CRD42022300907。研究结果共纳入五项试验进行分析,涉及 2814 名患者。ICI 加化疗可明显改善 OS(危险比 [HR],0.86;95% CI 0.78-0.94;P = .002)、PFS(HR,0.79;95% CI 0.63-0.99;P < .001)和 ORR(相对比 [RR],1.20;95% CI 1.11-1.30;P P > .05)。结论与化疗相比,ICI 加化疗是晚期 G/GEJ 癌症更有效的一线治疗方法,可改善 OS、PFS 和 ORR,但不会增加 TRAE 风险。这项研究将重新定义 ICI 联合化疗在 G/GEJ 癌一线治疗中的作用,为临床治疗提供参考。
{"title":"Immune Checkpoint Inhibitor Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Review and Meta-Analysis.","authors":"Lianghui Zhang, Lingli Huang, Zhixian Liu, Tao Ling","doi":"10.1177/15330338241273286","DOIUrl":"10.1177/15330338241273286","url":null,"abstract":"<p><p><b>Background:</b> Immune checkpoint inhibitor (ICI) plus chemotherapy is effective in advanced gastric or gastroesophageal junction (G/GEJ) cancer. This study aims to evaluate the clinical effect of first-line immunotherapy in combination with chemotherapy for advanced G/GEJ cancer<b>. Methods:</b> PubMed, Web of Science, Embase and Cochrane databases were systematically searched from the inception of the databases to December 2021. Randomized trials comparing ICI plus chemotherapy with chemotherapy in first-line treatment for advanced G/GEJ cancer were included. The outcomes were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and adverse events (AEs). Analyses were performed in Stata 14.0 software. The study protocol was registered with PROSPERO, number CRD42022300907. <b>Results:</b> Five trials were included for analysis, involving 2, 814 patients. ICI plus chemotherapy can significantly improve OS (hazards ratio [HR], 0.86; 95% CI 0.78-0.94; <i>P</i> = .002), PFS (HR, 0.79; 95% CI 0.63-0.99; <i>P</i> < .001) and ORR (relative ratio [RR], 1.20; 95% CI 1.11-1.30; <i>P</i> < .001). In safety analyses, there were no significant differences in incidence of all AEs, treatment-related adverse event (TRAE), TRAE of grade 3 or higher, serious TRAE and TRAE leading to death between two arms (<i>P</i> > .05). <b>Conclusions:</b> ICI plus chemotherapy is more effective first-line treatment for advanced G/GEJ cancer in contrast to chemotherapy regrading to improving OS, PFS and ORR, without increasing TRAE risk. This study will redefine the role of ICI in combination with chemotherapy in the first-line setting for G/GEJ cancer, and provide reference for clinical treatment.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"23 ","pages":"15330338241273286"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11307348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141898279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Clinical Retrospective Study on the Qualitative Value of Multimodal Ultrasonography for ACR-TIRADS 4 Thyroid Nodules Ranging from 1 cm to 1.5 cm. 关于 ACR-TIRADS 4 甲状腺结节(1 厘米至 1.5 厘米)的多模态超声定性价值的临床回顾性研究。
IF 2.7 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 DOI: 10.1177/15330338241297599
Xiaodan Yuan, Hong Wen, Mei Huang, Xumin Xie, Zhijun Yi, Shengkai Li

Introduction: This study explored the clinical value and application of ultrasound contrast imaging technology in the American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) TR4 benign and malignant thyroid nodules.

Methods: We retrospectively analyzed data from the medical records of 40 patients who met the inclusion criteria between January 2020 and December 2023. Each patient was evaluated using the ACR TI-RADS classification and contrast-enhanced ultrasound (CEUS). The agreement between pathological outcomes and ultrasound indicators and the diagnostic value and significance of each parameter were assessed.

Results: The diameters did not differ between benign and malignant nodules (P = 0.324). Ring enhancement was closely associated with benign thyroid nodules, with a negative predictive value of 100%. Homogeneous enhancement and enhancement intensity showed good diagnostic value for pathological results, with an area under the curve (AUC) > 0.8. This parameter showed a high diagnostic value for serial and parallel combinations of homogeneous enhancement and enhancement intensity, with a sensitivity of 77.8% and specificity of 85.7% for the serial combination and 100% and 71.4%, respectively. for the parallel combination.

Conclusion: Among ACR TI-RADS TR4 nodules, diameter 1.0-1.5 cm was not significantly correlated with a benign or malignant nature. Nodules featuring ring enhancement with ring-enhancing features should be considered benign. Similarly, nodules showing no, homogeneous, or high enhancement with clear borders on CEUS imaging may be benign. However, nodules with uneven low enhancement or unclear borders may be malignant. Therefore, uneven and low enhancement on CEUS imaging may have a high diagnostic value for malignant nodules. Moreover, the combination of these features may have even higher specificity.

导言:本研究探讨了超声对比成像技术在美国放射学会甲状腺成像报告和数据系统(ACR TI-RADS)TR4良性和恶性甲状腺结节中的临床价值和应用:我们对2020年1月至2023年12月期间符合纳入标准的40名患者的病历数据进行了回顾性分析。采用 ACR TI-RADS 分类和对比增强超声(CEUS)对每位患者进行了评估。评估了病理结果与超声指标之间的一致性以及各参数的诊断价值和意义:良性和恶性结节的直径没有差异(P = 0.324)。环状强化与良性甲状腺结节密切相关,其阴性预测值为 100%。均匀增强和增强强度对病理结果具有良好的诊断价值,曲线下面积(AUC)> 0.8。该参数对均匀增强和增强强度的串联和并联组合具有很高的诊断价值,串联组合的敏感性和特异性分别为 77.8%和 85.7%,并联组合的敏感性和特异性分别为 100%和 71.4%:结论:在 ACR TI-RADS TR4 结节中,直径 1.0-1.5 厘米的结节与良性或恶性无明显相关性。具有环状增强特征的结节应视为良性。同样,CEUS 成像显示无增强、均匀增强或高增强且边界清晰的结节也可能是良性的。然而,不均匀低增强或边界不清的结节可能是恶性的。因此,CEUS 成像上的不均匀低增强可能对恶性结节具有很高的诊断价值。此外,这些特征的组合可能具有更高的特异性。
{"title":"A Clinical Retrospective Study on the Qualitative Value of Multimodal Ultrasonography for ACR-TIRADS 4 Thyroid Nodules Ranging from 1 cm to 1.5 cm.","authors":"Xiaodan Yuan, Hong Wen, Mei Huang, Xumin Xie, Zhijun Yi, Shengkai Li","doi":"10.1177/15330338241297599","DOIUrl":"10.1177/15330338241297599","url":null,"abstract":"<p><strong>Introduction: </strong>This study explored the clinical value and application of ultrasound contrast imaging technology in the American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) TR4 benign and malignant thyroid nodules.</p><p><strong>Methods: </strong>We retrospectively analyzed data from the medical records of 40 patients who met the inclusion criteria between January 2020 and December 2023. Each patient was evaluated using the ACR TI-RADS classification and contrast-enhanced ultrasound (CEUS). The agreement between pathological outcomes and ultrasound indicators and the diagnostic value and significance of each parameter were assessed.</p><p><strong>Results: </strong>The diameters did not differ between benign and malignant nodules (P = 0.324). Ring enhancement was closely associated with benign thyroid nodules, with a negative predictive value of 100%. Homogeneous enhancement and enhancement intensity showed good diagnostic value for pathological results, with an area under the curve (AUC) > 0.8. This parameter showed a high diagnostic value for serial and parallel combinations of homogeneous enhancement and enhancement intensity, with a sensitivity of 77.8% and specificity of 85.7% for the serial combination and 100% and 71.4%, respectively. for the parallel combination.</p><p><strong>Conclusion: </strong>Among ACR TI-RADS TR4 nodules, diameter 1.0-1.5 cm was not significantly correlated with a benign or malignant nature. Nodules featuring ring enhancement with ring-enhancing features should be considered benign. Similarly, nodules showing no, homogeneous, or high enhancement with clear borders on CEUS imaging may be benign. However, nodules with uneven low enhancement or unclear borders may be malignant. Therefore, uneven and low enhancement on CEUS imaging may have a high diagnostic value for malignant nodules. Moreover, the combination of these features may have even higher specificity.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"23 ","pages":"15330338241297599"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142628688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent Innovative Machine Learning-Based Techniques for Breast Cancer Diagnosis and Treatment. 基于机器学习的乳腺癌诊断和治疗创新技术。
IF 2.7 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 DOI: 10.1177/15330338241298854
Ali Mahmoud, Mohammed Ghazal, Ayman El-Baz
{"title":"Recent Innovative Machine Learning-Based Techniques for Breast Cancer Diagnosis and Treatment.","authors":"Ali Mahmoud, Mohammed Ghazal, Ayman El-Baz","doi":"10.1177/15330338241298854","DOIUrl":"10.1177/15330338241298854","url":null,"abstract":"","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"23 ","pages":"15330338241298854"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11565613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142628752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of Machine Learning and Logic Regression Algorithms for Predicting Lymph Node Metastasis in Patients with Gastric Cancer: A two-Center Study. 机器学习与逻辑回归算法在预测胃癌患者淋巴结转移方面的比较:一项双中心研究
IF 2.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 DOI: 10.1177/15330338231222331
Tong Lu, Yu Fang, Haonan Liu, Chong Chen, Taotao Li, Miao Lu, Daqing Song

Objectives: This two-center study aimed to establish a model for predicting the risk of lymph node metastasis in gastric cancer patients using machine learning (ML) and logistic regression (LR) algorithms, and to evaluate its predictive performance in clinical practice.

Methods: Data of a total of 369 patients who underwent radical gastrectomy in the Department of General Surgery of Affiliated Hospital of Xuzhou Medical University (Xuzhou, China) from March 2016 to November 2019 were collected and retrospectively analyzed as the training group. In addition, data of 123 patients who underwent radical gastrectomy in the Department of General Surgery of Jining First People's Hospital (Jining, China) were collected and analyzed as the verification group. Besides, 7 ML and logistic models were developed, including decision tree, random forest, support vector machine (SVM), gradient boosting machine (GBM), naive Bayes, neural network, and LR, in order to evaluate the occurrence of lymph node metastasis in patients with gastric cancer. The ML model was established following 10 cross-validation iterations within the training dataset, and subsequently, each model was assessed using the test dataset. The model's performance was evaluated by comparing the area under the receiver operating characteristic curve of each model.

Results: Compared with the traditional logistic model, among the 7 ML algorithms, except for SVM, the other models exhibited higher accuracy and reliability, and the influences of various risk factors on the model were more intuitive.

Conclusion: For the prediction of lymph node metastasis in gastric cancer patients, the ML algorithm outperformed traditional LR, and the GBM algorithm exhibited the most robust predictive capability.

研究目的这项双中心研究旨在利用机器学习(ML)和逻辑回归(LR)算法建立预测胃癌患者淋巴结转移风险的模型,并评估其在临床实践中的预测性能:收集2016年3月至2019年11月在徐州医科大学附属医院(中国徐州)普外科接受根治性胃切除术的共369例患者的数据,作为训练组进行回顾性分析。此外,还收集了济宁市第一人民医院(中国济宁)普外科接受根治性胃切除术的123例患者数据作为验证组进行分析。此外,还建立了决策树、随机森林、支持向量机(SVM)、梯度提升机(GBM)、天真贝叶斯、神经网络和LR等7种ML和Logistic模型,以评估胃癌患者淋巴结转移的发生率。ML 模型在训练数据集中经过 10 次交叉验证迭代后建立,随后使用测试数据集对每个模型进行评估。通过比较每个模型的接收者操作特征曲线下面积来评估模型的性能:结果:与传统的逻辑模型相比,在 7 种 ML 算法中,除 SVM 外,其他模型均表现出较高的准确性和可靠性,且各种危险因素对模型的影响更为直观:结论:在预测胃癌患者淋巴结转移方面,ML算法优于传统的LR算法,其中GBM算法的预测能力最强。
{"title":"Comparison of Machine Learning and Logic Regression Algorithms for Predicting Lymph Node Metastasis in Patients with Gastric Cancer: A two-Center Study.","authors":"Tong Lu, Yu Fang, Haonan Liu, Chong Chen, Taotao Li, Miao Lu, Daqing Song","doi":"10.1177/15330338231222331","DOIUrl":"10.1177/15330338231222331","url":null,"abstract":"<p><strong>Objectives: </strong>This two-center study aimed to establish a model for predicting the risk of lymph node metastasis in gastric cancer patients using machine learning (ML) and logistic regression (LR) algorithms, and to evaluate its predictive performance in clinical practice.</p><p><strong>Methods: </strong>Data of a total of 369 patients who underwent radical gastrectomy in the Department of General Surgery of Affiliated Hospital of Xuzhou Medical University (Xuzhou, China) from March 2016 to November 2019 were collected and retrospectively analyzed as the training group. In addition, data of 123 patients who underwent radical gastrectomy in the Department of General Surgery of Jining First People's Hospital (Jining, China) were collected and analyzed as the verification group. Besides, 7 ML and logistic models were developed, including decision tree, random forest, support vector machine (SVM), gradient boosting machine (GBM), naive Bayes, neural network, and LR, in order to evaluate the occurrence of lymph node metastasis in patients with gastric cancer. The ML model was established following 10 cross-validation iterations within the training dataset, and subsequently, each model was assessed using the test dataset. The model's performance was evaluated by comparing the area under the receiver operating characteristic curve of each model.</p><p><strong>Results: </strong>Compared with the traditional logistic model, among the 7 ML algorithms, except for SVM, the other models exhibited higher accuracy and reliability, and the influences of various risk factors on the model were more intuitive.</p><p><strong>Conclusion: </strong>For the prediction of lymph node metastasis in gastric cancer patients, the ML algorithm outperformed traditional LR, and the GBM algorithm exhibited the most robust predictive capability.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"23 ","pages":"15330338231222331"},"PeriodicalIF":2.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10775719/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139404496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extracellular Vesicles Obtained From Lung Adenocarcinoma Cells Cultured Under Intermittent Hypoxia Induce M2 Macrophage Polarization via miR-20a-5p Delivery. 间歇性缺氧条件下培养的肺腺癌细胞产生的胞外囊泡通过 miR-20a-5p 递送诱导 M2 巨噬细胞极化
IF 2.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 DOI: 10.1177/15330338231219415
Yuanling Liu, Minzhen Lu, Feng Liu, Gang Xu, Congrui Feng, Yuluo Chen, Danyan Cai, Huake Sun, Yanjun Zeng, Jian Xie, Wei Ma, Xinglin Gao

Conclusion: These findings indicate that EVs obtained from lung adenocarcinoma cells cultured under IH deliver miR-20a-5p to promote M2 macrophage polarization by targeting PTEN.

结论这些研究结果表明,从在 IH 条件下培养的肺腺癌细胞中获得的 EVs 可传递 miR-20a-5p,通过靶向 PTEN 促进 M2 巨噬细胞极化。
{"title":"Extracellular Vesicles Obtained From Lung Adenocarcinoma Cells Cultured Under Intermittent Hypoxia Induce M2 Macrophage Polarization via miR-20a-5p Delivery.","authors":"Yuanling Liu, Minzhen Lu, Feng Liu, Gang Xu, Congrui Feng, Yuluo Chen, Danyan Cai, Huake Sun, Yanjun Zeng, Jian Xie, Wei Ma, Xinglin Gao","doi":"10.1177/15330338231219415","DOIUrl":"10.1177/15330338231219415","url":null,"abstract":"<p><p><b>Conclusion:</b> These findings indicate that EVs obtained from lung adenocarcinoma cells cultured under IH deliver miR-20a-5p to promote M2 macrophage polarization by targeting PTEN.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"23 ","pages":"15330338231219415"},"PeriodicalIF":2.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10851739/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139703507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
piR-1919609 Is an Ideal Potential Target for Reversing Platinum Resistance in Ovarian Cancer. piR-1919609 是逆转卵巢癌铂类抗性的理想潜在靶点
IF 2.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 DOI: 10.1177/15330338241249692
Ying Yan, Dan Tian, Bingbing Zhao, Zhuang Li, Zhijiong Huang, Kuina Li, Xiaoqi Chen, Lu Zhou, Yanying Feng, Zhijun Yang

Purpose: PIWI-interacting RNAs (piRNAs) are a type of noncoding small RNA that can interact with PIWI-like RNA-mediated gene silencing (PIWIL) proteins to affect biological processes such as transposon silencing through epigenetic effects. Recent studies have found that piRNAs are widely dysregulated in tumors and associated with tumor progression and a poor prognosis. Therefore, this study aimed to investigate the effect of piR-1919609 on the proliferation, apoptosis, and drug resistance of ovarian cancer cells.

Methods: In this study, we used small RNA sequencing to screen and identify differentially expressed piRNAs in primary ovarian cancer, recurrent ovarian cancer, and normal ovaries. A large-scale verification study was performed to verify the expression of piR-1919609 in different types of ovarian tissue, including ovarian cancer tissue and normal ovaries, by RT-PCR and to analyze its association with the clinical prognosis of ovarian cancer. The expression of PIWILs in ovarian cancer was verified by RT-PCR, Western blotting and immunofluorescence. The effects of piR-1919609 on ovarian cancer cell proliferation, apoptosis and drug resistance were studied through in vitro and in vivo models.

Results: (1) piR-1919609 was highly expressed in platinum-resistant ovarian cancer tissues (p < 0.05), and this upregulation was significantly associated with a poor prognosis and a shorter recurrence time in ovarian cancer patients (p < 0.05). (2) PIWIL2 was strongly expressed in ovarian cancer tissues (p < 0.05). It was expressed both in the cytoplasm and nucleus of ovarian cancer cells. (3) Overexpression of piR-1919609 promoted ovarian cancer cell proliferation, inhibited apoptosis, and promoted tumor growth in nude mice. (4) Inhibition of piR-1919609 effectively reversed ovarian cancer drug resistance.

Conclusion: In summary, we showed that piR-1919609 is involved in the regulation of drug resistance in ovarian cancer cells and might be an ideal potential target for reversing platinum resistance in ovarian cancer.

目的:PIWI-interacting RNAs(piRNAs)是一种非编码小 RNA,可与 PIWI-like RNA-mediated gene silencing(PIWIL)蛋白相互作用,通过表观遗传效应影响转座子沉默等生物过程。最近的研究发现,piRNA 在肿瘤中广泛失调,并与肿瘤进展和不良预后相关。因此,本研究旨在探讨 piR-1919609 对卵巢癌细胞增殖、凋亡和耐药性的影响:本研究利用小 RNA 测序技术筛选并鉴定了原发性卵巢癌、复发性卵巢癌和正常卵巢中差异表达的 piRNA。通过RT-PCR对piR-1919609在不同类型卵巢组织(包括卵巢癌组织和正常卵巢)中的表达进行了大规模验证研究,并分析了其与卵巢癌临床预后的相关性。通过RT-PCR、Western印迹和免疫荧光等方法验证了PIWILs在卵巢癌中的表达。通过体外和体内模型研究了 piR-1919609 对卵巢癌细胞增殖、凋亡和耐药性的影响:综上所述,我们发现 piR-1919609 参与了卵巢癌细胞耐药性的调控,可能是逆转卵巢癌铂类耐药性的理想潜在靶点。
{"title":"piR-1919609 Is an Ideal Potential Target for Reversing Platinum Resistance in Ovarian Cancer.","authors":"Ying Yan, Dan Tian, Bingbing Zhao, Zhuang Li, Zhijiong Huang, Kuina Li, Xiaoqi Chen, Lu Zhou, Yanying Feng, Zhijun Yang","doi":"10.1177/15330338241249692","DOIUrl":"10.1177/15330338241249692","url":null,"abstract":"<p><strong>Purpose: </strong>PIWI-interacting RNAs (piRNAs) are a type of noncoding small RNA that can interact with PIWI-like RNA-mediated gene silencing (PIWIL) proteins to affect biological processes such as transposon silencing through epigenetic effects. Recent studies have found that piRNAs are widely dysregulated in tumors and associated with tumor progression and a poor prognosis. Therefore, this study aimed to investigate the effect of piR-1919609 on the proliferation, apoptosis, and drug resistance of ovarian cancer cells.</p><p><strong>Methods: </strong>In this study, we used small RNA sequencing to screen and identify differentially expressed piRNAs in primary ovarian cancer, recurrent ovarian cancer, and normal ovaries. A large-scale verification study was performed to verify the expression of piR-1919609 in different types of ovarian tissue, including ovarian cancer tissue and normal ovaries, by RT-PCR and to analyze its association with the clinical prognosis of ovarian cancer. The expression of PIWILs in ovarian cancer was verified by RT-PCR, Western blotting and immunofluorescence. The effects of piR-1919609 on ovarian cancer cell proliferation, apoptosis and drug resistance were studied through in vitro and in vivo models.</p><p><strong>Results: </strong>(1) piR-1919609 was highly expressed in platinum-resistant ovarian cancer tissues (p < 0.05), and this upregulation was significantly associated with a poor prognosis and a shorter recurrence time in ovarian cancer patients (p < 0.05). (2) PIWIL2 was strongly expressed in ovarian cancer tissues (p < 0.05). It was expressed both in the cytoplasm and nucleus of ovarian cancer cells. (3) Overexpression of piR-1919609 promoted ovarian cancer cell proliferation, inhibited apoptosis, and promoted tumor growth in nude mice. (4) Inhibition of piR-1919609 effectively reversed ovarian cancer drug resistance.</p><p><strong>Conclusion: </strong>In summary, we showed that piR-1919609 is involved in the regulation of drug resistance in ovarian cancer cells and might be an ideal potential target for reversing platinum resistance in ovarian cancer.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"23 ","pages":"15330338241249692"},"PeriodicalIF":2.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11072069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140863996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Plasma CircCYP24A1 as a Novel Biomarker of Esophageal Squamous Cell Carcinoma. 血浆CircCYP24A1作为食管鳞状细胞癌的新生物标志物
IF 2.7 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 DOI: 10.1177/15330338241295313
Ruolan Zhang, Jianlin Liu, Hang Yang, Jinsong Tan, Rong Xiong, Yun Liu, Gang Feng, Guiqin Song, Kang Liu

Background: A clinical challenge in esophageal squamous cell carcinoma (ESCC) remains the lack of applicable plasma biomarkers for screening and diagnosis. Circular RNAs (circRNAs) hold great potential as biomarkers for cancer. The study aims to explore a circRNA as a potential plasma biomarker for screening strategies and diagnostic approaches to ESCC.

Methods: Upregulated circRNAs were identified through RNA sequencing, with circCYP24A1 being identified as the target circRNA. Fluorescence in situ hybridization was employed to detect the expression of circCYP24A1 in ESCC tissue microarrays, aiming to assess the expression of circCYP24A1 in a large population and its correlation with clinical indicators. Subsequently, qRT-PCR analysis was performed on plasma samples from both ESCC patients and healthy controls to evaluate the expression levels of circCYP24A1, exploring its potential as a biomarker. Finally, the functions of circCYP24A1 were validated through CCK-8 assay, wound healing assay, trans-well assays and western blot assays.

Results: CircCYP24A1 demonstrated upregulation in both plasma and tissues, exhibiting correlations with lymph node metastasis, TNM staging, and prognosis in ESCC. The circCYP24A1 achieved a perfect area under the curve of 0.94 for the diagnosis of ESCC, and an area under the curve of 0.76 for the prediction of lymph node metastasis. Furthermore, functional loss assays revealed that circCYP24A1 effectively promotes the epithelial-mesenchymal transition and tumor metastasis in vitro.

Conclusions: CircCYP24A1 emerges as a potential plasma diagnostic biomarker and a predictive factor for LNM for ESCC.

背景:食管鳞状细胞癌(ESCC)的临床难题仍然是缺乏可用于筛查和诊断的血浆生物标志物。环状 RNA(circRNA)作为癌症生物标志物具有巨大潜力。本研究旨在探索一种circRNA作为潜在的血浆生物标志物,用于ESCC的筛查策略和诊断方法:方法:通过RNA测序确定了上调的circRNA,其中circCYP24A1被确定为目标circRNA。采用荧光原位杂交技术检测 ESCC 组织芯片中 circCYP24A1 的表达,旨在评估大量人群中 circCYP24A1 的表达及其与临床指标的相关性。随后,对 ESCC 患者和健康对照者的血浆样本进行了 qRT-PCR 分析,以评估 circCYP24A1 的表达水平,探索其作为生物标志物的潜力。最后,通过CCK-8试验、伤口愈合试验、转孔试验和Western印迹试验验证了circCYP24A1的功能:结果:circCYP24A1在血浆和组织中均有上调,与ESCC的淋巴结转移、TNM分期和预后相关。circCYP24A1 诊断 ESCC 的曲线下面积为 0.94,预测淋巴结转移的曲线下面积为 0.76。此外,功能丧失试验显示,circCYP24A1能有效促进上皮-间质转化和体外肿瘤转移:CircCYP24A1是一种潜在的血浆诊断生物标记物,也是ESCC淋巴结转移的预测因子。
{"title":"Plasma CircCYP24A1 as a Novel Biomarker of Esophageal Squamous Cell Carcinoma.","authors":"Ruolan Zhang, Jianlin Liu, Hang Yang, Jinsong Tan, Rong Xiong, Yun Liu, Gang Feng, Guiqin Song, Kang Liu","doi":"10.1177/15330338241295313","DOIUrl":"10.1177/15330338241295313","url":null,"abstract":"<p><strong>Background: </strong>A clinical challenge in esophageal squamous cell carcinoma (ESCC) remains the lack of applicable plasma biomarkers for screening and diagnosis. Circular RNAs (circRNAs) hold great potential as biomarkers for cancer. The study aims to explore a circRNA as a potential plasma biomarker for screening strategies and diagnostic approaches to ESCC.</p><p><strong>Methods: </strong>Upregulated circRNAs were identified through RNA sequencing, with circCYP24A1 being identified as the target circRNA. Fluorescence in situ hybridization was employed to detect the expression of circCYP24A1 in ESCC tissue microarrays, aiming to assess the expression of circCYP24A1 in a large population and its correlation with clinical indicators. Subsequently, qRT-PCR analysis was performed on plasma samples from both ESCC patients and healthy controls to evaluate the expression levels of circCYP24A1, exploring its potential as a biomarker. Finally, the functions of circCYP24A1 were validated through CCK-8 assay, wound healing assay, trans-well assays and western blot assays.</p><p><strong>Results: </strong>CircCYP24A1 demonstrated upregulation in both plasma and tissues, exhibiting correlations with lymph node metastasis, TNM staging, and prognosis in ESCC. The circCYP24A1 achieved a perfect area under the curve of 0.94 for the diagnosis of ESCC, and an area under the curve of 0.76 for the prediction of lymph node metastasis. Furthermore, functional loss assays revealed that circCYP24A1 effectively promotes the epithelial-mesenchymal transition and tumor metastasis in vitro.</p><p><strong>Conclusions: </strong>CircCYP24A1 emerges as a potential plasma diagnostic biomarker and a predictive factor for LNM for ESCC.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"23 ","pages":"15330338241295313"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11660079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regulation and Therapeutic Application of Long non-Coding RNA in Tumor Angiogenesis. 长非编码 RNA 在肿瘤血管生成中的调控和治疗应用。
IF 2.7 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 DOI: 10.1177/15330338241273239
Shuo Zhang, Yunxiu Xia, Weiwei Chen, Hongliang Dong, Bingjie Cui, Cuilan Liu, Zhiqiang Liu, Fei Wang, Jing Du

Tumor growth and metastasis rely on angiogenesis. In recent years, long non-coding RNAs have been shown to play an important role in regulating tumor angiogenesis. Here, we review the multidimensional modes and relevant molecular mechanisms of long non-coding RNAs in regulating tumor angiogenesis. In addition, we summarize new strategies for tumor anti-angiogenesis therapies by targeting long non-coding RNAs. The aim of this study is to provide new diagnostic targets and treatment strategies for anti-angiogenic tumor therapy.

肿瘤的生长和转移依赖于血管生成。近年来,长非编码 RNA 在调控肿瘤血管生成中发挥了重要作用。在此,我们综述了长非编码 RNA 在调控肿瘤血管生成中的多维模式和相关分子机制。此外,我们还总结了针对长非编码 RNA 的肿瘤抗血管生成治疗新策略。本研究旨在为肿瘤抗血管生成治疗提供新的诊断靶点和治疗策略。
{"title":"Regulation and Therapeutic Application of Long non-Coding RNA in Tumor Angiogenesis.","authors":"Shuo Zhang, Yunxiu Xia, Weiwei Chen, Hongliang Dong, Bingjie Cui, Cuilan Liu, Zhiqiang Liu, Fei Wang, Jing Du","doi":"10.1177/15330338241273239","DOIUrl":"10.1177/15330338241273239","url":null,"abstract":"<p><p>Tumor growth and metastasis rely on angiogenesis. In recent years, long non-coding RNAs have been shown to play an important role in regulating tumor angiogenesis. Here, we review the multidimensional modes and relevant molecular mechanisms of long non-coding RNAs in regulating tumor angiogenesis. In addition, we summarize new strategies for tumor anti-angiogenesis therapies by targeting long non-coding RNAs. The aim of this study is to provide new diagnostic targets and treatment strategies for anti-angiogenic tumor therapy.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"23 ","pages":"15330338241273239"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11307360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141898281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Technology in Cancer Research & Treatment
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1